Cargando…

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534082/ https://www.ncbi.nlm.nih.gov/pubmed/31165048 http://dx.doi.org/10.3389/fonc.2019.00417

Ejemplares similares

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis
por: Pickard, Amanda J., et al.
Publicado: (2016)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
por: Liu, Shuang, et al.
Publicado: (2020)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
por: Urban, Daniel J., et al.
Publicado: (2017)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Modeling HSV-1 Latency in Human Embryonic Stem Cell-Derived Neurons
por: Pourchet, Aldo, et al.
Publicado: (2017)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
por: Reinbold, Raphael, et al.
Publicado: (2022)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
por: Kim, Ja Eun, et al.
Publicado: (2015)

Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes
por: Walker, Olivia S., et al.
Publicado: (2016)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Mutants for Drosophila Isocitrate Dehydrogenase 3b Are Defective in Mitochondrial Function and Larval Cell Death
por: Duncan, Dianne M., et al.
Publicado: (2017)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

A Non-invasive Radiomic Method Using (18)F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma
por: Li, Longfei, et al.
Publicado: (2019)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
por: Liu, Zhen, et al.
Publicado: (2014)

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report
por: Morimoto, Takayuki, et al.
Publicado: (2022)

Erratum to: Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase–Mutant Glioblastoma: A Multicenter Study
por: Uetani, Hiroyuki, et al.
Publicado: (2023)

Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers
por: Lee, Wen-Yuan, et al.
Publicado: (2014)

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers
por: Thamim, Masthan, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_paguavej5ppmuhocvf4t0ptt06